Network Medicine-Based Repurposing of Mesalazine for Atherosclerosis Treatment
- 10 September 2025
- journal article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (5) , 1058-1069
Abstract
Atherosclerosis remains a leading cause of cardiovascular disease and mortality worldwide, despite advancements in statin therapies. Here, we aimed to identify potential anti-atherosclerosis drugs by an integrated approach combining network medicine-based prediction with empirical validation. Among the top drugs predicted by the preferred algorithm, mesalazine─a drug traditionally used to treat inflammatory bowel disease, was selected for in vivo validation in ApoE-/- mouse model of atherosclerosis. After an 8-week treatment period, mesalazine significantly inhibited atherosclerosis progression by reducing total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels, while increasing high-density lipoprotein cholesterol (HDL-C) levels. Additionally, it decreased the plaque area and hepatic steatosis. Gene expression analysis via RT-qPCR revealed that mesalazine downregulated key genes associated with atherosclerosis. These findings highlight the potential of mesalazine as a repurposed anti-atherosclerosis drug and offer novel insights into drug screening for atherosclerosis treatment.Keywords
Funding Information
- Science and Technology Program of Guizhou Province (ZK[2022]General 587)
This publication has 50 references indexed in Scilit:
- PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IκB kinase β (IKK-β)Bioorganic & Medicinal Chemistry Letters, 2007
- Prostaglandin-endoperoxide synthase (PTGS1 and PTGS2) expression and prostaglandin production by normal monkey ovarian surface epitheliumFertility and Sterility, 2006
- Expression of Human Myeloperoxidase by Macrophages Promotes Atherosclerosis in MiceCirculation, 2005
- Ertiprotafib Improves Glycemic Control and Lowers Lipids via Multiple MechanismsMolecular Pharmacology, 2005
- Role of PPARγ in macrophage biology and atherosclerosisTrends in Endocrinology & Metabolism, 2004
- Regression of Coronary Atherosclerosis by SimvastatinCirculation, 2004
- PPARs and the complex journey to obesityNature Medicine, 2004
- The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitisAlimentary Pharmacology & Therapeutics, 2002
- Simvastatin Has Anti-Inflammatory and Antiatherosclerotic Activities Independent of Plasma Cholesterol LoweringArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Retardation of Coronary Atherosclerosis: The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and Other Angiographic TrialsCardiovascular Drugs and Therapy, 1997